RxDoctor Payments Data

Syed Ahmed, MD

Internal Medicine · Houston, TXNPI 1255378352

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 35 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations.

$726in general payments, 2019–2025

Across 35 payments — averaging $20.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$154
  • AbbVie$105
  • Lilly USA, LLC$105
  • Amgen$50
  • Dexcom, Inc.$49
  • Supreme Orthopedic Systems, LLC$46
  • plus $217 from 8 others
$24,022in research payments, 2019–2025

Across 6 payments — averaging $4003.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Teva Pharmaceuticals USA, Inc.$15K
  • AstraZeneca$9K

What the payments were for

  • Food & beverage$726100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$726 in reported general payments places this provider in the 65th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas →

Medicare billing

Part B allowed, 2024
$33,635
Medicare patients
152
Services billed
389

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Atorvastatin Calcium55$374
Albuterol Sulfate HfaAlbuterol Sulfate14$365
Tamsulosin Hcl28$346
Metformin Hcl39$292
Levothyroxine Sodium35$263
Lisinopril48$263
Gabapentin15$252
Losartan Potassium34$217
Amlodipine Besylate34$192
Pantoprazole Sodium19$188
Omeprazole12$159
Naproxen13$153
Trazodone Hcl14$147
Ibuprofen18$140
Finasteride14$138

Paid to pharmacies, not to this prescriber.

Other internal medicine in Houston

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →